-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-11-07
Values as of: 2024-11-07
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 31/01/2006
Primary Benchmark: S&P Biotechnology Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.88 (-0.59%) |
USD 40.46B |
FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.29 (-0.41%) |
USD 2.91B |
FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.65 (+0.58%) |
USD 1.19B |
XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+0.78 (+0.84%) |
USD 0.22B |
IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.15 (+0.57%) |
USD 0.15B |
SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+0.37 (+0.87%) |
USD 0.13B |
XHS | SPDR® S&P Health Care Service.. | 0.35 % |
+2.06 (+2.13%) |
USD 0.08B |
HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.27 (+0.91%) |
USD 0.06B |
BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.45 (-0.66%) |
USD 0.02B |
BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
+0.29 (+0.93%) |
USD 0.01B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
MATH | Metalpha Technology Holdi.. | 0.00 % | 1.35 % |
+0.01 (+0%) |
USD 0.05B |
INAV | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -61.54% | 24% | F | 7% | C- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -61.54% | 24% | F | 8% | B- | ||
Trailing 12 Months | |||||||
Capital Gain | -48.44% | 24% | F | 8% | B- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -48.44% | 24% | F | 9% | A- | ||
Trailing 5 Years | |||||||
Capital Gain | -59.10% | 19% | F | 11% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -59.10% | 19% | F | 12% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 0.38% | 24% | F | 36% | F | ||
Dividend Return | 0.46% | 24% | F | 25% | F | ||
Total Return | 0.08% | 26% | F | 3% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 32.98% | 19% | F | 31% | F | ||
Risk Adjusted Return | 1.38% | 24% | F | 23% | F | ||
Market Capitalization | 3.15B | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.